<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Cytokines such as interleukin (IL)-6 and granulocyte colony-stimulating factor (G-CSF) are important <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> promoters </plain></SENT>
<SENT sid="1" pm="."><plain>This study has investigated the functional significance of the increased circulation of galectin-3, a common feature in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and in particular those with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, on cytokine secretion from the blood vascular endothelium in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: The effects of galectin-3 on secretion of cytokines from human microvascular lung endothelial cells were assessed in vitro by cytokine array and in vivo in mice </plain></SENT>
<SENT sid="3" pm="."><plain>The consequences of galectin-3-induced cytokine secretion on endothelial cell behaviors were determined, and the relationship between the levels of circulating galectin-3 and cytokines in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with and without <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> was investigated </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Galectin-3 at pathologic concentrations found in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> induces secretion of IL-6, G-CSF, sICAM-1, and granulocyte macrophage colony-stimulating factor from blood vascular endothelial cells in vitro and in mice </plain></SENT>
<SENT sid="5" pm="."><plain>These cytokines autocrinely/paracrinely interact with the vascular endothelium to increase the expressions of endothelial cell surface <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules integrinαvβ1, E-selectin, ICAM-1, and VCAM-1, resulting in increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell-endothelial <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and increased endothelial cell migration and tubule formation </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, higher serum galectin-3 levels correlated significantly with increased serum G-CSF, IL-6, and sICAM1 concentrations </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: The increased circulation of galectin-3 in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> induces secretion of several <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-promoting cytokines from the blood vascular endothelium that enhances endothelial cell activities in <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Targeting the actions of circulating galectin-3 in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therefore represents a promising therapeutic strategy to reduce <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and improve survival </plain></SENT>
<SENT sid="9" pm="."><plain>Clin <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Res; 19(7); 1693-704. ©2013 AACR </plain></SENT>
</text></document>